Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARIPOSA-2
jRCT2031210358Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of amivantamab, lazertinib, pemetrexed and carboplatin in non-small cell lung cancer (NSCLC) (5 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started Dec 2021; status: active, not recruiting.
02
Drugs
amivantamablazertinibpemetrexedcarboplatin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2031210358.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210358.